ArticleJournal of gastrointestinal cancer2026
Efficacy and Safety of Modified GTX as Second-Line Therapy in Advanced Pancreatic Adenocarcinoma: A Prospective Cohort Study.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvanced pancreatic adenocarcinoma lacks a universally accepted second-line chemotherapy regimen following progression on FOLFIRINOX or Gemzar/Abraxane. In a previous retrospective study at AUBMC, the modified GTX regimen showed good tolerability and a 33% response rate. This prospective study aimed to evaluate radiological response, toxicity, and survival outcomes of modified GTX in patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma who progressed after first-line chemotherapy.
methodsEligible patients from the American University of Beirut Medical Center (AUBMC) treated between March 2013 and May 2019 (age ≥ 18, ECOG performance status 0-2) received modified GTX in 28-day cycles: docetaxel 40 mg/m² (days 1, 15), gemcitabine 1000 mg/m² (days 8, 22), and capecitabine 625 mg/m² orally twice daily (days 6-10, 20-24). Radiological response, toxicity (CTCAE v4.0), progression-free survival (PFS), and overall survival (OS) were assessed using the Kaplan-Meier method.
resultsAmong 44 patients (31 males, 13 females), 25 (56.8%) had received FOLFIRINOX and 19 (43.2%) had received gemcitabine-based regimens as first-line therapy. The median PFS was 2 months (95% CI: 1.5-2.8 months) and median OS was 8 months (95% CI: 6.2-9.8 months). Common adverse events included anemia (93.3%), neutropenia (48.9%), thrombocytopenia (24.4%), mucositis/oral thrush (33.3%), nausea/vomiting (20.5%), diarrhea (22.2%), and infection (24.4%). Grade 3/4 toxicities included anemia (19.7%), neutropenia (28.9%), and thrombocytopenia (20.1%).
conclusionModified GTX demonstrated clinical activity with a manageable toxicity profile, thereby suggesting its potential as a second-line treatment option in advanced pancreatic adenocarcinoma. Larger prospective studies are warranted to further validate our findings.
Indexed as
Identifiers
42216989What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.